A COVID-19 vaccine candidate composed of SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles

Autor: Darielys Santana-Mederos, Rocmira Perez-Nicado, Yanet Climent, Laura Rodriguez, Belinda Sanchez Ramirez, Sonia Perez-Rodriguez, Meybi Rodriguez, Claudia Labrada, Tays Hernandez, Marianniz Diaz, Ivette Orosa, Ubel Ramirez, Reynaldo Oliva, Raine Garrido, Felix Cardoso, Mario Landys, Roselyn Martinez, Humberto Gonzalez, Tamara Hernandez, Rolando Ochoa-Azze, Jose L. Perez, Juliet Enriquez, Nibaldo Gonzalez, Yenicet Infante, Luis A. Espinosa, Yassel Ramos, Luis Javier González, Carmen Valenzuela, Ana Victoria Casadesus, Briandy Fernandez, Gertrudis Rojas, Beatriz Pérez-Massón, Yaima Tundidor, Ernesto Bermudez, Claudia A. Plasencia, Tammy Boggiano, Eduardo Ojito, Fabrizio Chiodo, Sonsire Fernandez, Françoise Paquet, Cheng Fang, Guang-Wu Chen, Daniel G. Rivera, Yury Valdes-Balbin, Dagmar Garcia-Rivera, Vicente Verez Bencomo

Publikováno v: RSC Chemical Biology
RSC Chemical Biology, Royal Society of Chemistry, In press, ⟨10.1039/D1CB00200G⟩
Santana-Mederos, D, Perez-Nicado, R, Climent, Y, Rodriguez, L, Ramirez, B S, Perez-Rodriguez, S, Rodriguez, M, Labrada, C, Hernandez, T, Diaz, M, Orosa, I, Ramirez, U, Oliva, R, Garrido, R, Cardoso, F, Landys, M, Martinez, R, Gonzalez, H, Hernandez, T, Ochoa-Azze, R, Perez, J L, Enriquez, J, Gonzalez, N, Infante, Y, Espinosa, L A, Ramos, Y, González, L J, Valenzuela, C, Casadesus, A V, Fernandez, B, Rojas, G, Pérez-Massón, B, Tundidor, Y, Bermudez, E, Plasencia, C A, Boggiano, T, Ojito, E, Chiodo, F, Fernandez, S, Garcia-Rivera, D, Fang, C, Chen, G-W, Rivera, D G, Valdes-Balbin, Y, Garcia-Rivera, D & Verez Bencomo, V 2022, ' A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and : Neisseria meningitidis outer membrane vesicles ', RSC Chemical Biology, vol. 3, no. 2, pp. 242-249 . https://doi.org/10.1039/d1cb00200g
RSC Chemical Biology, 3(2), 242-249. Royal Society of Chemistry

SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ca97b53fb4a278f7101794d646b985
https://hal.archives-ouvertes.fr/hal-03519898

A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial

Autor: Vicente Verez-Bencomo, Kalet Leon-Monzon, Yaima Zuniga-Rosales, Yanet Jerez-Barcelo, Yury Valdés-Balbín, Carmen Valenzuela-Silva, Marianniz Diaz-Hernandez, Yanet Climent-Ruiz, Juliet Enriquez-Puertas, Maria de los A. Garcia-Garcia, Delia Porto-Gonzalez, Raul Gonzalez-Mugica, Dagmar García-Rivera, Belinda Sanchez-Ramirez, Rocmira Perez-Nicado, Guang-Wu Chen, Pedro Pablo Guerra-Chaviano, Luis Herrera Martinez, Mireida Rodriguez-Acosta, Arturo Chang-Monteagudo, Tays Hernandez-Garcia, Rolando Ochoa-Azze, Rinaldo Puga-Gomez, Luis Dairon Rodríguez-Prieto, Ivette Orosa-Vazquez, Laura Ruiz-Villegas, Yenisey Triana-Marrero, Enrique Noa-Romero, Beatriz Marcheco-Teruel, Consuelo Macías-Abraham, Laura M. Rodríguez-Noda

We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excelle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d49b54584eb53e0bda49ce6494529dce
https://doi.org/10.1101/2021.02.22.21252091

Studying the Humoral Response against SARS-CoV-2 in Cuban COVID-19 Recovered Patients

Autor: Ivette Orosa Vázquez, Marianniz Díaz, Yaima Zúñiga Rosales, Klayris Amada, Janoi Chang, Ernesto Relova Hernández, Yaima Tundidor, Hilda Roblejo Balbuena, Giselle Monzón, Bárbara Torres Rives, Enrique Noa Romero, Danay Carrillo Valdés, Irinia Valdivia Álvarez, Aurora Delahanty Fernández, Claudia Díaz, Joaquín Solozabal, Mileidys Gil, Belinda Sánchez, Gertrudis Rojas, Beatriz Marcheco, Tania Carmenate

Publikováno v: Journal of Immunology Research, Vol 2024 (2024)

Understanding the immune response generated by SARS-CoV-2 is critical for assessing efficient therapeutic protocols and gaining insights into the durability of protective immunity. The current work was aimed at studying the specific humoral responses

Externí odkaz: https://doaj.org/article/9ab37f77e4cf4be4a5086f33ab50f49f

A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

Autor: Arturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, Consuelo Macías-Abraham, Laura Rodríguez-Noda, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Rocmira Perez-Nicado, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María de los Ángeles García-García, Yanet Jerez-Barceló, Yenisey Triana-Marrero, Laura Ruiz-Villegas, Luis Dairon Rodríguez-Prieto, Rinaldo Puga-Gómez, Pedro Pablo Guerra-Chaviano, Yaíma Zúñiga-Rosales, Beatriz Marcheco-Teruel, Mireida Rodríguez-Acosta, Enrique Noa-Romero, Juliet Enríquez-Puertas, Delia Porto-González, Olivia Fernández-Medina, Anet Valdés-Zayas, Guang-Wu Chen, Luís Herrera-Martínez, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Verez-Bencomo

Publikováno v: The Lancet Regional Health. Americas, Vol 4, Iss , Pp 100079- (2021)

Background: As a first step towards a vaccine protecting COVID-19 convalescents from reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods: Thirty COVID-19 convalescents aged 22-57 years were studied: convalescents of mild COVID

Externí odkaz: https://doaj.org/article/54ac04bcc70849c995125a973cce9fdb